Human papillomavirus antigen presented on major histocompatibility complex molecule

Human papillomavirus antigens presented on major histocompatibility complex molecules refer to short peptides (typically 8–14 amino acids) derived from viral proteins of HPV that are processed and displayed on the cell surface by MHC class I or II molecules. These peptide-MHC complexes are recognized by T-cell receptors and are essential for the activation of the adaptive immune response against HPV-infected or HPV-transformed (cancerous) cells. Presentation of HPV antigens on MHC molecules is the primary mechanism through which the immune system detects and eliminates HPV-positive tumor cells or infected cells. This process is the central target of therapeutic vaccines, adoptive T-cell therapies, and is indirectly leveraged by immune checkpoint inhibitors in HPV-driven malignancies. The combination of a viral antigen and an MHC molecule is not a typical receptor or single gene product, but rather a complex molecular target used in modern immunotherapeutic strategies. The naming given ("HPV antigens presented on MHC molecules") refers to a molecular complex, not a singular gene/protein, so it is not a canonical molecular target in the classical sense (like "Epidermal growth factor receptor"), but is widely used as the target for T-cell–based immunotherapies. The term requires further specification for structured databases.

Other names

HPV MHC antigen complexHPV-derived peptide-MHC complexHPV peptide-MHCHPV antigen/MHC complex

T-cell receptor recognition: Drugs/therapies enhance or induce T-cell recognition of HPV peptide-MHC complexes, leading to cytotoxic T cell-mediated killing of infected or tumor cells.